Receptor News and Research

RSS

Mapping the year-one weight trajectory after stopping GLP-1s

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost weight – but beyond this, their weight regain plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge.

4 Mar 2026

GLP-1 drugs may be effective at treating and preventing substance use disorders

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major addictive substances studied, suggesting these drugs target a common biological pathway underlying addiction.

4 Mar 2026

Nearly 70 weeks after infection, long COVID patients show no detectable inflammation in blood tests

A controlled Norwegian case-control study examined circulating biomarkers of inflammation and neuronal injury in people with long COVID about 69 weeks after infection. The researchers found no significant differences in systemic inflammatory or neuroinjury markers compared with recovered controls after statistical correction.

4 Mar 2026

Enhancing myelination may help sustain therapeutic effects of psychedelic-assisted PTSD treatment

Post-traumatic stress disorder (PTSD) is not only characterized by strongly encoded traumatic memories, but also by disrupted coordination across brain networks.

4 Mar 2026

Mathematical model identifies how estrogen protects women from high blood pressure

High blood pressure, or hypertension, affects more than one billion people worldwide and is a leading cause of heart disease and stroke.

4 Mar 2026

Iron found essential for growth and survival of beta cells

An international team of scientists, led by researchers from the Free University of Brussels (VUB) and UZ Brussel, has made a major breakthrough in the study of how our bodies maintain healthy blood sugar levels.

3 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Persistent taste dysfunction after COVID 19 linked to cellular abnormalities

Scientists have identified molecular and structural changes in taste buds that may explain why a small subset of people experience long-term taste loss after COVID-19 infection.

2 Mar 2026

Blocking growth hormone receptor may improve treatment response in lung cancer

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

2 Mar 2026

Study identifies a promising strategy to treat brain metastases

A new study from researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung cancer.

2 Mar 2026

The surprising neurological benefits of GLP-1s

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

2 Mar 2026

Common cardio drugs proven safe in myeloma patients

Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international research.

1 Mar 2026

Investigating microglia’s role in Alzheimer’s pathology

Announcing a new article publication for BIO Integration journal. Alzheimer's disease (AD) is a neurodegenerative disorder and the leading cause of dementia worldwide. Microglia, as central nervous system (CNS) resident macrophages, are key to AD pathology. Indeed, microglia aggregation around amyloid-β (Aβ) deposits is an AD hallmark.

1 Mar 2026

PEX38 protein offers new target against tropical trypanosome diseases

The pathogens that cause tropical diseases rely on an essential protein that is absent from all other organism. This discovery opens the possibility for targeted treatment.

27 Feb 2026

Protein partnership enhances innate immune sensing of viral RNA

Study reveals how two proteins cooperate in a key early step of antiviral detection, as reported by researchers at Science Tokyo.

27 Feb 2026

Mendelian randomization study reveals opposing roles for IL6 and IL6R in long-term mortality

A new research paper was published in Volume 18 of Aging-US on February 6, 2026, titled "Causal effects of inflammation on long-term mortality: a Mendelian randomization study."

27 Feb 2026

Researchers discover critical vulnerability shared by pathogens causing tropical diseases

Researchers working with Professor Ralf Erdmann at Ruhr University Bochum, Germany, have discovered a critical vulnerability shared by the pathogens that cause African sleeping sickness, Chagas disease, and leishmaniasis.

27 Feb 2026

Serial liquid biopsies reveal evolution in advanced prostate cancer

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that androgen receptor (AR) alterations consistently emerged and were linked to poorer outcomes across therapies.

26 Feb 2026

Ultra-sensitive CAR T cells target solid tumors

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors.

26 Feb 2026

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

25 Feb 2026